Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo Plus Yervoy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Pharmaceutical Investing
Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor Pharmaceutical Investing
NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER Market News
Adjuvant Treatment With Merck's KEYTRUDA® Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial Life Science Investing
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma Pharmaceutical Investing
Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors with Substantial Losses to Contact the Firm Pharmaceutical Investing
Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients Pharmaceutical Investing
Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients Pharmaceutical Investing
Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer Life Science Investing
Bristol Myers Squibb Withdraws Supplemental Biologics License Application for Reblozyl® for Non-transfusion Dependent Beta Thalassemia Pharmaceutical Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
